Latest news with #vitiligo
Yahoo
17 hours ago
- Health
- Yahoo
Increased Psychological and Social Impact of Vitiligo Drives Demand for More Effective Therapies
Key market opportunities for vitiligo treatment include a shift toward personalized therapies addressing immune dysregulation, increasing awareness and early diagnosis, and innovative technologies such as JAK inhibitors, phototherapy advancements, and AI diagnostics. The sector benefits from rising demand for aesthetic solutions and holistic, patient-centric care approaches. Vitiligo Treatment Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment - Global Strategic Business Report" has been added to global market for Vitiligo Treatment was estimated at US$1.5 Billion in 2024 and is projected to reach US$2.1 Billion by 2030, growing at a CAGR of 5.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Vitiligo Treatment market. The growth in the vitiligo treatment market is being propelled by a combination of medical, economic, and societal factors that are reshaping both patient demand and therapeutic innovation. One of the key drivers is the increasing prevalence of vitiligo globally, with estimates suggesting that it affects up to two percent of the population. Improved awareness and earlier diagnosis are leading more individuals to seek treatment, which is expanding the patient base and creating new market opportunities. Advances in immunology and dermatological research are encouraging pharmaceutical companies to invest in the development of novel therapies, particularly targeted treatments like JAK inhibitors and stem cell-based solutions. Regulatory agencies are also playing a supportive role by granting designations such as orphan drug status to vitiligo treatments, thereby incentivizing innovation and accelerating clinical development. The rising demand for aesthetic solutions, fueled by social media and the growing emphasis on personal appearance, is further boosting interest in effective vitiligo therapies. In parallel, the wellness movement and a broader cultural shift toward embracing diversity and skin positivity are influencing how the condition is perceived and managed. Health insurers and governments are beginning to acknowledge the psychological burden of vitiligo, leading to expanded coverage for certain treatments and increased funding for research. Technological advancements in digital health, including telemedicine and AI-powered diagnostics, are making treatment more accessible, especially in remote or underserved regions. Partnerships between pharmaceutical companies, dermatology clinics, and advocacy organizations are also helping to raise public awareness and reduce stigma. Together, these interconnected trends are creating a dynamic and optimistic outlook for the vitiligo treatment market, one that prioritizes innovation, accessibility, and comprehensive care. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc. and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Segmental Vitiligo segment, which is expected to reach US$1.4 Billion by 2030 with a CAGR of a 6.3%. The Non-Segmental Vitiligo segment is also set to grow at 3.4% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $412.6 Million in 2024, and China, forecasted to grow at an impressive 8.6% CAGR to reach $417.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Scope Of Study: Type (Segmental Vitiligo, Non-Segmental Vitiligo) Vitiligo Treatment (Therapy Treatment, Surgical Treatment, Medication Treatment) End-Use (Hospitals End-Use, Ambulatory Clinics End-Use, Other End-Uses) Key Attributes: Report Attribute Details No. of Pages 377 Forecast Period 2024 - 2030 Estimated Market Value in 2024 1.5 Billion Forecasted Market Value by 2030 2.1 Billion Compound Annual Growth Rate 5.3% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Vitiligo Treatment - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Awareness of Skin Health Throws the Spotlight on Unmet Needs in Vitiligo Treatment Increased Psychological and Social Impact of Vitiligo Drives Demand for More Effective Therapies Here's the Story How Advances in Autoimmune Research Are Unlocking New Therapeutic Pathways Emergence of Janus Kinase Inhibitors Propels Innovation in Topical and Systemic Treatment Options Growing Focus on Personalized Dermatology Supports Development of Tailored Vitiligo Interventions Here's How Phototherapy Advancements Are Enhancing Treatment Efficacy and Accessibility Rising Interest in Melanocyte Regeneration Boosts Research in Cell-Based and Stem Cell Therapies Cosmetic Industry Collaboration Expands Availability of Camouflage Products and Adjunctive Care Expansion of Dermatology Telehealth Platforms Improves Access to Diagnosis and Long-Term Management Clinical Trials in Underrepresented Populations Address Gaps in Ethnic Skin Treatment Data Growing Consumer Demand for Non-Steroidal Alternatives Encourages Natural and Herbal Product Innovation Shift Toward Holistic and Multimodal Care Models Reinforces the Value of Integrative Vitiligo Treatment Approaches FOCUS ON SELECT PLAYERS AbbVie Inc. Amgen Inc. Astellas Pharma Inc. Aurobindo Pharma Ltd. Bausch Health Companies Inc. Bristol Myers Squibb Dermavant Sciences Dr. Reddy`s Laboratories Encore Dermatology Inc. Ferrer Internacional S.A. Glenmark Pharmaceuticals Ltd. Incyte Corporation Kamada Ltd. LEO Pharma A/S Medimetriks Pharmaceuticals Pfizer Inc. Sanofi Strata Skin Sciences Sun Pharmaceutical Industries Teva Pharmaceutical Industries For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Vitiligo Treatment Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
19 hours ago
- Health
- Medscape
Race, Ethnicity Influences Depression Risk in Vitiligo
TOPLINE: In a study, Black and Hispanic patients with vitiligo were at a significantly greater risk for depression than control individuals, which was not the case for White and Asian patients with vitiligo. METHODOLOGY: Researchers conducted a retrospective cross-sectional study of 1087 patients with vitiligo using electronic health records from the National Institutes of Health All of Us Program between 2018 and 2024. They were compared with 5435 individuals without vitiligo, matched by age, sex, race/ethnicity, education, income, and insurance status. In both groups, the mean age was 63.2 years; about 63% were women; 49% were White, 19% were Black, 3% were Asian, and 24% were Hispanic patients. The primary outcome was risk for depression after adjusting for comorbidities such as autoimmune and thyroid diseases, Hashimoto thyroiditis, and diabetes. TAKEAWAY: Overall, patients with vitiligo showed an increased risk for depression (adjusted odds ratio [aOR], 1.34; 95% CI, 1.16-1.54) compared with those without vitiligo. Black patients with vitiligo had more than a twofold higher risk for depression (aOR, 2.13; 95% CI, 1.55-2.91) than Black patients without vitiligo. Hispanic patients also had a significantly higher risk for depression (aOR, 1.45; 95% CI, 1.09-1.94), and non-Hispanic patients were also at a higher risk for depression (aOR, 1.29; 95% CI, 1.09-1.52) than Hispanic and non-Hispanic control individuals without vitiligo, respectively. The risk for depression in White individuals (aOR, 1.06; 95% CI, 0.85-1.29) and in Asian individuals with vitiligo (aOR, 0.70; 95% CI, 0.15-2.38) was not significantly increased when compared with White and Asian patients without vitiligo, respectively. IN PRACTICE: 'These findings underscore significant variation in the mental health burden of vitiligo across racial and ethnic groups,' the study authors wrote. 'Black and Hispanic patients with vitiligo,' they added, 'experience significantly elevated depression risk, potentially reflecting greater lesion visibility, cultural stigma, and differences in access to mental health and dermatologic services.' SOURCE: The study was led by Matthew J. Yan, BS, BA, Division of Dermatology, Department of Medicine at the University of California, Los Angeles, and was published online on August 5 in JAAD International. LIMITATIONS: The study did not assess vitiligo lesion visibility, treatment details, or age of onset. Sample sizes for Asian patients were small and could limit generalizability. DISCLOSURES: The study did not receive any funding. One author disclosed receiving research support, advisory, and speaker fees from AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, LEO, UCB, Janssen Pharmaceuticals, Eli Lilly and Company, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Regeneron, and Pfizer. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
07-07-2025
- Health
- Medscape
Study: Rx Delayed in Half of US Children With Vitiligo
TOPLINE: In a US real-world analysis, only 51.5% of children with vitiligo received any treatment within 2 years of diagnosis, less often than adults. METHODOLOGY: Researchers analyzed data from the TriNetX US Collaborative Network of patients with two or more medical claims for vitiligo. The study included 5253 adults and an equal number of sex- and race-matched pediatric patients. Treatment included phototherapies (narrowband ultraviolet [UVB], psoralen and UVA [PUVA], and excimer laser), topical treatments (calcineurin inhibitors, corticosteroids, calcipotriene, and ruxolitinib), and systemic therapies (corticosteroids and oral immunomodulators). Outcomes were prescribing patterns in children within 1 year of diagnosis and treatment initiation rates in adult and pediatric patients within 2 years post-diagnosis. TAKEAWAY: In 2024, topical corticosteroids were the most commonly prescribed treatment in children (73.0%), followed by systemic corticosteroids (57.0%), topical calcineurin inhibitors (49.8%), and topical ruxolitinib (11.3%), approved by the FDA for treating nonsegmental vitligo in patients aged 12 years or older. Within 2 years of diagnosis, 51.5% of pediatric and 56.1% of adult patients received treatment, indicating that treatment initiation rates were significantly lower among pediatric patients than among adult patients (hazard ratio [HR], 0.91; 95% CI, 0.86-0.96). Pediatric patients had lower treatment initiation rates across all modalities than adults: phototherapy (HR, 0.82; 95% CI, 0.71-0.94), topical treatment (HR, 0.92; 95% CI, 0.87-0.97), and systemic therapy (HR, 0.63; 95% CI, 0.59-0.67). IN PRACTICE: This study showed that '48.5% of children with vitiligo remained treatment-free within 2 years post-diagnosis' and had a lower probability of starting treatment than adults, the authors wrote. Factors that might contribute to this difference, they added, included disease recognition, considering lack of access to pediatric dermatology care in some areas, and 'insurance providers classifying vitiligo as a cosmetic rather than medical condition leading to limited coverage and access, particularly to newer therapies.' SOURCE: This study was led by Serena Yun-Chen Tsai, MD, MMSc, Department of Dermatology, Massachusetts General Hospital, Boston. It was published online on July 2 in the Journal of the American Academy of Dermatology. LIMITATIONS: This study relied on coded diagnoses and excluded patients with only one encounter, possibly inflating treatment rates. Disease severity, location, and care outside TriNetX sites were not captured. DISCLOSURES: The authors reported having no funding information. One author received funding from the Society for Pediatric Dermatology/Pediatric Dermatology Research Alliance. Two authors reported receiving advisory fees and having ties with Alys Pharmaceuticals, Avoro, Barinthus Bio NA, Cour Pharma, Incyte, Matchpoint Therapeutics, NexImmune, Vividion, and Sanofi. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
The Sun
27-06-2025
- Entertainment
- The Sun
Coronation Street star Georgia May Foote issues ‘tough' update as she opens up about her health condition
CORONATION Street star Georgia May Foote has issues a "tough" update on her "hard to deal with" ongoing health condition. Actress Georgia, 34, who is best-known for playing the role as Katy Armstrong in the hit ITV soap, revealed two years ago that she had been diagnosed with vitiligo. 5 5 5 The soap star has actually had the skin condition - where white spots or patches can be seen in different areas of her body - since 2020. Today the Coronation Street legend gave fans an update on her "tough" journey. The actress took to social media as she opened up on the effects of vitiligo, which is a chronic autoimmune disorder. Sharing a slew of pics which showed how the condition had affected her hands and arms, she wrote a lengthy post which read: " Happy World Vitiligo Day. "If you are new to my page or don't already know, I developed vitiligo in 2020. "This has been one of the craziest journeys I have ever had. I was misdiagnosed for a while before I begged to be seen by a dermatologist, which then took another year. I was then diagnosed with vitiligo. "Vitiligo is a skin condition where my immune systems attacks the melanocytes which produce the melanin in my skin. "This causes white patches all over my body, which continue to spread daily. "They become bigger and show up new places all the time!." Giving fans an update on how she has been doing, Georgia said: "This year has been particularly tough as it has spread onto my face now. I have good days and bad days with the condition! Coronation Street star Georgia May Foote sparks concern as she reveals she's been too ill to eat for five days "Sometimes I'm really down about it and other days I feel very special. "Unfortunately there is no understanding why this happens. ( stress deffo doesn't help in my case ) I have the very annoying side effect of itching! "And until the uk pass the cream Opzelure there will be no way of bringing my pigment back!" The soap star ended with the message with: "People who love me don't give it a second glance. Vitiligo: What are the symptoms? The main symptom of vitiligo is flat, white spots or patches on your skin. Initially, the vitiligo may start as a patch of skin that is paler than the rest. Gradually, the patch will become completely white as the pigment in the skin begins to fade. Vitiligo does not cause discomfort to your skin, such as dryness, but patches may occasionally be itchy, guidance states. "That's all that matters it's a hard thing to deal with, but I am a tough and I will not let it get to me. "I have an amazing family and group of friends who mean the world to me. "Happy world vitiligo day to my gang." In March, Georgia revealed how she is advocating for the NHS to approve the prescription of medical cream, Ruxolitinib, which is reported to help those with the condition. The actress shot to fame in Corrie in 2010, and was on the soap until 2015. She's also known for her appearances in the BBC school drama, Grange Hill, from 2005 for three years.
Daily Mail
25-06-2025
- Entertainment
- Daily Mail
Demi Sims proudly shows off her 'patches' in a slew of candid bikini snaps as she raises awareness for National Vitiligo Day
Demi Sims showcased her vitiligo in a series of candid bikini snaps on Instagram on Wednesday as she raised awareness for National Vitiligo Day. The TV personality, 28, who has previously spoken openly about growing up with the skin condition, shared several empowering photos, urging fans to 'wear their skin condition with confidence.' The former TOWIE star reflected on her journey with self-confidence, revealing how much her mindset has changed since she first developed vitiligo as a teenager. Admitting she used to be 'so shy' about her patches, Demi said she now embraces them completely. Captioning her inspiring post, she wrote: 'Happy national vitiligo day (party hat emojis), ive had my patches since I was 16 years old, and I live with them everyday! 'They stand out a lot more when I'm tanned so summer time used to be scary for me. I used to be so so shy about them growing up I went to the drs and tried different medication, but now I couldn't care less, 'I wouldn't get rid of them if a dr came to me with a cure, they built me to gain my confidence that I walk with today (love heart emoji). 'Love to everyone today who has a skin condition and don't forget to wear it with confidence because I've noticed the people who are around me and love me for me, would still love me just as much with or without my patches, 'As it's all about the good person you are on the inside, you're all perfect the way you are (love heart emoji).' In 2022, the star opened up to OK! Magazine about her skin condition. She said: 'I want everyone who has vitiligo to feel comfortable. I wanted to do it because I wanted to feel proud of myself and I wanted to make other people who have vitiligo feel proud, too. 'There's nothing worse than getting messages on social media from people asking me how I cover it up. I want people to embrace it and be happy in their skin.' She added that she still gets 'new patches all the time' and detailed how her biggest ones have stopped getting bigger now. She continued: 'The newest one is on my wrist, which I got about a month ago. I thought they had stopped last year but I notice new patches every now and then. My biggest ones have all stopped now.' The beauty took to her Instagram account after posing naked for the magazine and shared a sweet message raising awareness. She penned at the time: '*Vitiligo awareness* Well where do I start … a few weeks ago I got completely starkers infront of a camera crew and photographers to send the public who are living with a skin condition a message to love yourself. 'This has got to be the most nervous I had ever been. I done the extreme so I could feel what it was like going back in time again; the first time I ever came out about my vitiligo. 'And yes it was scary and yes I felt uncomfortable and out of my comfort zone for a minute, but that minute didn't last very long when I started to remember why and who I was doing this for, and that's when the confidence started too ooze out.' She continued: 'This article isn't only for helping people with skin conditions it's also for making people who haven't got a skin condition to recognise it and also be aware of how nervous it can make you feel. 'I hope I can help at least 1 person from this post, and I will continue to speak more openly about vitiligo. 'I have been filming on our new show wearing hardly any makeup in some scenes so viewers can see it, it's fair to say I'm no longer hiding. I'm out and proud and my vitiligo is here too stay.' WHAT IS VITILIGO? Vitiligo is one of the most common autoimmune skin diseases and is caused by a lack of melanin, the pigment that gives skin its colour. Late singer Michael Jackson always said he was blighted by a rare skin disease called vitiligo - but his claim is shrouded in controversy as many experts are adamant he wasn't a sufferer. Canadian fashion model Winnie Harlow is a known sufferer. The body's immune system attacks the pigment cells, mistaking them for foreign invaders. This causes painless white patches on exposed areas such as the face and fingers, although they can also appear on the wrists, around the eyes, groin, armpits and inside the mouth. The disease affects around one in 200 people, and about 50 per cent develop their first symptoms before the age of 20, though it's not clear why. However, 'stressful' events, such as childbirth, hormone changes or even cuts to the skin, may trigger it — there is also a genetic link. There is no cure, but some treatments can reverse pigment loss if used early enough.
